鮮馳達控股(01175.HK)中期收入約13.33億元 同比大增約2133.2%
格隆匯11月29日丨鮮馳達控股(01175.HK)宣佈,截至2019年9月30日止6個月,公司錄得收入約人民幣13.33億元(單位下同),同比增2133.25%; 公司擁有人應占虧損1705.1萬元,同比收窄22.79%;基本及攤薄每股虧損1.04分;不建議派息。
據悉,集團收益同比大幅增加約2133.2%。集團於本期間收益增加乃由於目標市場的迅速擴張及品牌的設立。期內,集團八大主要銷售區域業務迅速增長且銷售網絡得以加強,令於市場所佔市場份額有所增加。公司擁有人應占期內虧損減少乃主要由於其銷售增長所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.